Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024

Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Wet Age-Related Macular Degeneration (Wet AMD): Understanding

Wet Age-Related Macular Degeneration (Wet AMD): Overview

Wet Age-Related Macular Degeneration (Wet AMD) is a significant form of age-related macular degeneration characterized by the growth of abnormal blood vessels beneath the retina. These vessels can leak fluid and blood, leading to scarring of the macula and rapid vision loss if left untreated. Wet AMD is a serious condition that affects a smaller percentage of individuals compared to the dry form but progresses more rapidly and can cause severe visual impairment. The key hallmark of Wet AMD is the development of pathologic choroidal neovascular membranes (CNVM) under the retina, which can result in central vision loss over a relatively short period. This form of AMD requires prompt diagnosis and treatment to prevent irreversible vision damage.

Age-Related Macular Degeneration (AMD) is a multifactorial disease influenced by various risk factors. These include older age, elevated total serum cholesterol, micronutrient deficiency, smoking, family history, hypertension, cardiovascular disease, and visible light exposure. Genetic predisposition is a significant factor, with at least 34 genetic loci and 52 gene variants associated with AMD. Inflammation is a key player in the pathogenesis of wet AMD, with polymorphisms of complement factor H being notable mutations linked to the disease. These mutations suggest the crucial role of complement activation in the development of wet AMD, highlighting the complex interplay of genetic and environmental factors in this vision-threatening condition.

Wet Age-Related Macular Degeneration (Wet AMD) presents with various symptoms that can significantly impact vision. Individuals with Wet AMD may experience gaps or dark spots in their vision, especially noticeable in the morning, along with fading colors. Objects may appear distorted or change shape, and straight lines can appear bent or wavy. Bright light may become uncomfortable, and adapting to changes in light environments may be challenging. Reading difficulties, disappearing words, and distorted perception of sizes and colors are common. Additionally, individuals may struggle with glare, have trouble seeing fine details clearly, and may notice objects appearing differently to each eye. In severe cases, visual hallucinations in the blind spot at the center of the field of vision can occur, a phenomenon known as Charles Bonnet syndrome. These symptoms highlight the complexity and impact of Wet AMD on visual function and quality of life.

The primary treatments for Wet Age-Related Macular Degeneration (Wet AMD) aim to slow disease progression and prevent further vision loss. Anti-VEGF (vascular endothelial growth factor) therapy, which involves injections of medications like aflibercept, bevacizumab, brolucizumab, or ranibizumab directly into the eye, is the most common and effective treatment. These drugs block the abnormal blood vessel growth and leakage that characterize Wet AMD. Nutritional supplements containing vitamins and minerals, such as the AREDS2 formula, may also help slow the progression of dry AMD and prevent Wet AMD in the other eye. In some cases, photodynamic therapy using a light-activated drug or laser surgery may be used to seal leaking blood vessels. Regular eye exams and prompt treatment are crucial to manage Wet AMD and preserve vision.

""Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wet Age-Related Macular Degeneration (Wet AMD) pipeline landscape is provided which includes the disease overview and Wet Age-Related Macular Degeneration (Wet AMD) treatment guidelines. The assessment part of the report embraces, in depth Wet Age-Related Macular Degeneration (Wet AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet AMD) R&D. The therapies under development are focused on novel approaches to treat/improve Wet Age-Related Macular Degeneration (Wet AMD).

Wet Age-Related Macular Degeneration (Wet AMD) Emerging Drugs Chapters

This segment of the Wet Age-Related Macular Degeneration (Wet AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet AMD) Emerging Drugs

• RGX-314: REGENXBIO

RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is being developed as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF.

ATMOSPHERE, the first of two planned pivotal trials for the evaluation of subretinal delivery of RGX-314 in patients with wet AMD, is active and enrolling patients. In addition, the company is enrolling patients in AAVIATE, a Phase II trial for the treatment of wet AMD using suprachoroidal delivery of RGX-314. A Biologics License Application (BLA) is expected to be submitted to the United States Food and Drug Administration (FDA) in 2024 based on two pivotal trials, ASCENT and the ongoing ATMOSPHERE trial. ASCENT clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada.

• 9MW 0211: Mabwell (Shanghai) Bioscience

9MW 0211 is a recombinant anti-VEGF humanized monoclonal antibody obtained based on rabbit monoclonal antibody and humanized transformation technology, which is a category 1 therapeutic biological product. It can specifically bind to the most active VEGF-A in the VEGF family, block its binding to receptors on the surface of endothelial cells, reduce vascular permeability and block the formation and development of new blood vessels, and reduce the leakage caused by new blood vessels, so as to achieve the purpose of treating eye diseases related to neovascularization such as neovascular (wet) age-related macular degeneration. The drug is currently being evaluated in Phase II/III clinical trial to treat patients with wet-AMD.

• SYL1801: Sylentis

SYL1801 is a chemically modified siRNA, engineered using Sylentis proprietary SirFinder, which inhibits the synthesis of Nrarp. It is administered as an eye drop solution to transcriptionally down-regulate the expression of Nrarp, a target different from those against which the usual anti-angiogenic therapies based on anti-VEGF agents are directed. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with wet AMD.

• OLX10212: OliX Pharmaceuticals

OLX10212 is a novel cell penetrating asymmetric small interference RNA being developed by OliX Pharmaceuticals in Phase I stage of development for the treatment of wet-MAD. OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD.

Further product details are provided in the report……..

Wet Age-Related Macular Degeneration (Wet AMD): Therapeutic Assessment

This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet AMD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Wet Age-Related Macular Degeneration (Wet AMD)

There are approx. 70+ key companies which are developing the therapies for Wet Age-Related Macular Degeneration (Wet AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet AMD) drug candidates in the most advanced stage, i.e. Phase III include, REGENXBIO.

• Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Wet Age-Related Macular Degeneration (Wet AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wet Age-Related Macular Degeneration (Wet AMD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet AMD) drugs.

Wet Age-Related Macular Degeneration (Wet AMD) Report Insights

• Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Wet Age-Related Macular Degeneration (Wet AMD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Wet Age-Related Macular Degeneration (Wet AMD) drugs?
• How many Wet Age-Related Macular Degeneration (Wet AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wet Age-Related Macular Degeneration (Wet AMD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• OliX Pharmaceuticals
• Frontera Therapeutics
• Kyowa Kirin
• Boehringer Ingelheim
• Clearside Biomedical
• PanOptica
• EyePoint Pharmaceuticals
• Unity Biotechnology
• AngioLab
• Kinarus Therapeutics
• Sylentis
• Mabwell (Shanghai) Bioscience
• Samsung Bioepis
• Sandoz
• Outlook Therapeutics
• Molecular Partners
• Sam Chun Dang Pharm
• TOT Biopharm

Key Products

• OLX10212
• FT-003
• KHK4951
• BI 836880
• AXT107
• PAN-90806
• EYP-1901
• UBX1325
• ALS-L1023
• KIN001
• SYL1801
• 9MW 0211
• SB15
• SOK583A1
• ONS-5010
• Abicipar pegol
• SCD411
• TAB014

Please Note: It will take 4-5 business days to complete the report upon order confirmation. Show more